Skip to main content

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

MIGRANOSTIC: Estandardització d’un procediment diagnòstic molecular per a la migranya mitjançant biomarcadors de miARN

IP: Patricia Pozo Rosich
Collaborators: Laila Asskour , Eulalia Gine Cipres, Anna Cristina Segú Cristina, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 64938.52
Reference: SLT041/25/000055
Duration: 04/12/2025 - 03/12/2026

Digitalization in Migraine

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR23/00065
Duration: 01/01/2024 - 31/12/2027

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 30/06/2026

BiOmarcadores Moleculares y clínicos de respuesta al tratamiento en los Ataques de Migraña (Estudio MAMBO).

IP: Marta Torres Ferrús
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Laura Gómez Dabó, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI22/01530
Duration: 01/01/2023 - 30/06/2026

Related news

On April 18 and 19, the Vall d’Hebron Research Institute (VHIR) will once again join the Science Festival 2026 with a diverse and participatory program focused on health, innovation, and citizen engagement in research.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Irene Salvador Roses

Irene Salvador Roses

Research technician
Donation and transplantation of organs, tissues and cells
Read more
Maria Luisa Pancorbo Lerma

Maria Luisa Pancorbo Lerma

Predoctoral researcher
Maternal and Fetal Medicine
Read more
Pau Sarle Valles

Pau Sarle Valles

Predoctoral researcher
Neurodegenerative Diseases
Read more
Ruperto Olivero Soldevila

Ruperto Olivero Soldevila

Research assistant
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.